Perbedaan Merck Tbk. dan Trimegah Karya Pratama Tbk.: Merck Tbk. diperdagangkan di Rp3.840 (kapitalisasi pasar 1,7 T, volume 24 jam 37,6 rb), sedangkan Trimegah Karya Pratama Tbk. diperdagangkan di Rp139 (kapitalisasi pasar 272,02 M, volume 24 jam 55,79 jt). Perbedaan utamanya: Merck Tbk. jauh lebih besar — sekitar 6,2× kapitalisasi pasar Trimegah Karya Pratama Tbk., dan Trimegah Karya Pratama Tbk. lebih aktif diperdagangkan (55,79 jt vs 37,6 rb). Mana yang lebih baik tergantung tujuan investasimu.
| MERK | UVCR | |
|---|---|---|
Kapitalisasi Pasar | 1,7 T | 272,02 M |
Volume | 37,6 rb | 55,79 jt |
Lot | 376 | 557,94 rb |
Perputaran | 144,47 jt | 7,75 M |
Harga Rata-rata | 3.842,23 | 138,88 |
Nilai Transaksi | 144,47 jt | 7,75 M |
Harga Ekuilibrium Indikatif | 3.840 | 139 |
Volume Ekuilibrium Indikatif | 7 | 6,83 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Selengkapnya di halaman MERK →PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Selengkapnya di halaman UVCR →